dc.contributor.author | Calzada, David | |
dc.contributor.author | Cremades-Jimeno, Lucía | |
dc.contributor.author | Pedro, María Ángeles de | |
dc.contributor.author | Baos, Selene | |
dc.contributor.author | Rial, Manuel | |
dc.contributor.author | Sastre Domínguez, Joaquín | |
dc.contributor.author | Quiralte, Joaquín | |
dc.contributor.author | Florido, Fernando | |
dc.contributor.author | Lahoz, Carlos | |
dc.contributor.author | Cárdaba, Blanca | |
dc.contributor.other | UAM. Departamento de Medicina | es_ES |
dc.contributor.other | Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD) | es_ES |
dc.date.accessioned | 2020-09-17T13:09:20Z | |
dc.date.available | 2020-09-17T13:09:20Z | |
dc.date.issued | 2019-11-04 | |
dc.identifier.citation | Scientific Reports 9 (2019): 15942 | en_US |
dc.identifier.issn | 2045-2322 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10486/691947 | |
dc.description.abstract | Olive-pollen allergy is one of the leading causes of respiratory allergy in Mediterranean countries and
some areas of North America. Currently, allergen-specific immunotherapy is the only etiophatogenic
treatment. However, this approach is not fully optimal, safe, or effective. Thus, efforts continue in
the search for novel immunotherapy strategies, being one of the most promising the use of peptides
derived from major allergens. This work tries to determine the therapeutic potential and safety of 5
dodecapeptides derived from the main allergen of olive-pollen allergy, Ole e 1. The immunomodulatory
capacity of these peptides was studied using peripheral blood mononuclear cells (PBMCs) obtained from
19 olive-pollen-allergic patients and 10 healthy controls. We determined the capacity of these peptides
to inhibit the proliferative response toward olive-pollen allergenic extract and to induce the regulatory
cytokines, IL-10 and IL-35. To test the safety and absence of allergenicity of the peptides, the basophil
activation was analyzed by flow-cytometry, using peripheral blood. The results showed that two of
five peptides inhibited near to 30% the proliferative response against the total olive-pollen allergenic
extract in olive-pollen-allergic patients. Inhibition increased to nearly 35% when the 5 peptides were
used in combination. In both cases, a statistically significant induction of IL-10 and IL-35 secretion
was observed in the supernatants of allergic patients PBMCs cultures. None of the 5 peptides induced
basophil activation and cross-link inflammatory cell-bound IgE. In conclusion, these results open up
new possibilities in the treatment of olive-pollen allergy, which could solve some of the problems facing current therapy approaches | en_US |
dc.description.sponsorship | Supported by research grants PI13/01730, PI17/01682 cofinanced by FEDER, CIBERES
(ISCIII, 0013), and RETIC (RD09/0076/00101) from the Fondo de Investigación Sanitaria (Ministerio de Sanidad
y Consumo, Spain). D. Calzada was supported by a contract from Comunidad de Madrid (PEJD-2016/BMD-
2682, Sistema de Garantía Juvenil), L. Cremades-Jimeno was supported by a contract from MINECO (PEJ-2014-A-31609, Sistema de Garantía Juvenil) and MA. de Pedro was supported by a contract from Comunidad
de Madrid (PEJ-2017-AI/SAL-5938, Sistema de Garantía Juvenil), all cofinanced by Fondo Social Europeo (FSE)
and Iniciativa de Empleo Juvenil (IEJ). S. Baos was supported by Fundación Conchita Rábago and PI17/01682. | en_US |
dc.format.extent | 12 pag. | es_ES |
dc.format.mimetype | application/pdf | en |
dc.language.iso | eng | en |
dc.publisher | Nature Research (part of Springer Nature) | en_US |
dc.relation.ispartof | Scientific Reports | en_US |
dc.rights | © 2019 The Author(s) | en_US |
dc.subject.other | Olive-pollen | en_US |
dc.subject.other | Allergy | en_US |
dc.subject.other | Novel immunotherapy strategies | en_US |
dc.subject.other | Peptides | en_US |
dc.title | Therapeutic potential of peptides from Ole e 1 in olive-pollen allergy | en_US |
dc.type | article | en |
dc.subject.eciencia | Medicina | es_ES |
dc.relation.publisherversion | https://doi.org/10.1038/s41598-019-52286-3 | es_ES |
dc.identifier.doi | 10.1038/s41598-019-52286-3 | es_ES |
dc.identifier.publicationfirstpage | 15942-1 | es_ES |
dc.identifier.publicationissue | 9 | es_ES |
dc.identifier.publicationlastpage | 15942-12 | es_ES |
dc.relation.projectID | Gobierno de España. PI13/01730 | es_ES |
dc.relation.projectID | Gobierno de España. PI17/01682 | es_ES |
dc.relation.projectID | Gobierno de España. RD09/0076/00101 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | en |
dc.rights.cc | Reconocimiento | es_ES |
dc.rights.accessRights | openAccess | en |
dc.authorUAM | Sastre Domínguez, Joaquín (267984) | |
dc.facultadUAM | Facultad de Medicina | |